Targets › ANGPTL3
6 programs from 6 companies in 8 trials: 3 Phase 3, 3 Phase 1, 2 Phase 2; Metabolic and endocrine; next expected readout Dec 2026.
Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). (UniProt, Q9Y5C1)
Open in Phaseline: the race on ANGPTL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | Zodasiran ANGPTL3 antisense oligonucleotide | ANGPTL3 | Phase 3 | Homozygous Familial Hypercholesterolemia | Aug 2027 |
| Visirna Therapeutics HK | VSA003 RNA interference (RNAi) therapeutic targeting ANGPTL3 | ANGPTL3 | Phase 3 | Homozygous Familial Hypercholesterolemia (HoFH) | Dec 2027 |
| Regeneron Pharmaceuticals | ALN-ANG3 ANGPTL3 inhibitor | ANGPTL3 | Phase 2 | Diabetic Kidney Disease (DKD); Healthy Volunteers With Hyperlipidemia | Dec 2026 |
| Eddingpharm (Zhuhai) | EDP167 siRNA targeting ANGPTL3 | ANGPTL3 | Phase 2 | Homozygous Familial Hypercholesterolemia (HoFH) | Mar 2027 |
| CRISPR Therapeutics | CTX310 In vivo CRISPR-Cas9 gene editing targeting ANGPTL3 | ANGPTL3 | Phase 1 | Cardiovascular | Jun 2027 |
| Verve Therapeutics | VERVE-201 Base-editing technology to inactivate ANGPTL3 gene expression in hepatocytes | ANGPTL3 | Phase 1 | Hypercholesterolemia | Dec 2027 |
Homozygous Familial Hypercholesterolemia (HoFH) (2) Homozygous Familial Hypercholesterolemia (2) Diabetic Kidney Disease (DKD) (1) Healthy Volunteers With Hyperlipidemia (1) Hypercholesterolemia (1) Cardiovascular (1)
small molecule (3), other (2), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.